Research Progress in the Effect Evaluation of GLP1-1 Agonists

© 2022 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Glucagon-like peptide-1 (GLP-1) promotes insulin secretion, inhibits glucagon secretion, and repairs pancreatic islet cell function to enhance islet cell proliferation and regeneration. Furthermore, it includes a mechanism for weight loss and angiocarpy protection. This study covers the comparison of GLP-1 agonists with DPP-4 inhibitors and GLT-2 inhibitors, the mechanism of GLP-1 agonists, and its research possibilities based on a summary of current clinical tests of GLP-1 receptor agonists.

References

Wang L, He J, et al., 2013, Prevalence and Control of Diabetes in Chinese Adults. JAMA, 310(9): 948- 959.

Fan H, Bhurke S, Jia G, et al., 2019, Differences and Similarities in Diabetes Research between China and the USA. Int J Environ Res Public Health, 16(16): E2989.

Ao J. 2014, Research on Analysis of Adverse Reactions to Antidiabetic Drugs. Diabetes New World, 14: 22.

Zhang H, 2017, Research Progress on Adverse Reactions of Oral Hypoglycemic Drugs. Tianjin Pharmacy, 02: 75-78.

Monamin M, Ahren B, Dicembrini I, et al., 2013, Dipetidyl Peptidase-4Inhibitors and Cardiovascular Risk: A Meta-Analysis of Randomized Clinical Trisls. Disbetes Obes Metab, 15(2): 112-120.

Lu J, 2014, Consensus on Clinical Application of Hypoglycemic Drugs based on Glucagon Like Peptide 1. Chinese Journal of Diabetes Mellitus, 01: 14-20.

Lu D, Ma X, Guo X, 2016, Research Progress on the Role of Dipeptidyl Peptidase-4 Cardiovascular System. Chinese Journal of Diabetes Mellitus, 11: 1049-1051.

Hong TP, 2013, Comparison of the Effects of Pancreatin on Patients with Type-2 Diabetes Mellitus. Chin J Diabetes, (9): 861-864

Meng Y, Liu W, Liu F, et al., 2013, Research Progress on Anti Type-2 Diabetes Drugs. Drugs & Clinic, 03: 461-464.

Li W, Wag Q, 2019, Research Progress on the Safety of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes. Pharmaceutical Care and Research, 01: 1-4.

Yokono M, Takasu T, Hayashizaki Y, et al., 2014, SGLT2 Selective Inhibitor Ipragliflozin Reduces Body Fat Mass by Increasing Fatty Acid Oxidation in High-Fat Diet-Induced Obese Rats. Eur J Pharmacol, 727(1) :66-74.

Vivian EM. 2014, Sodium-Glucose Co-Transporter 2 (SGLT2) in Hibitors: A Growing Class of Antidiabetic Agents.Drugs in Context, 3: 212264.

Mu M, Xu L, 2011, New Progress in the Development of Oral Anti-Diabetes Drugs. Medical Recapitulate, 10: 1537-1539.

Malik RE, et al., 2020, The Relationship Between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c Among Patients with Type 2 Diabetes. American Diabetes Association 80th Scientific Sessions.

Mody R, et al., 2020, Dulaglutide Shows Sustained A1C reduction: Two-year US Real-World Study. American Diabetes Association 80th Scientific Sessions.

Nikolaidis L, Elahi D, Shen YT, et al., 2005, Active Metabolite of GLP-1 Mediates Myocardial Glucose Uptake and Improves Left Ventricular Per-Formance in Conscious Dogs with Dilated Cardiomyopathy. Am JPhysiol Heart Circ Physiol, 289(6): 2401-2408.

Anholm C, Kumarathurai P, Jürs A, et al., 2019, Liraglutide Improves the Beta-Cell Function without Increasing Insulin Secretion during a Mixed Meal in Patients, Who Exhibit Well-Controlled Type 2 Diabetes and Coronary Artery Disease. Diabetol Metab Syndr, 11: 42.

Previous article in this issue

Next article in this issue